Immuno-Biological Laboratories Co., Ltd. (4570.T)
JPY 444.0
(0.23%)
JPY 444.0
(0.23%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.61 Billion JPY | 12.85% |
| 2022 | 1.43 Billion JPY | -15.89% |
| 2021 | 1.7 Billion JPY | -7.22% |
| 2020 | 1.83 Billion JPY | -22.51% |
| 2019 | 2.37 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.68 Billion JPY | 4.17% |
| 2023 Q2 | 1.43 Billion JPY | 0.51% |
| 2023 Q1 | 1.42 Billion JPY | -0.5% |
| 2023 Q3 | 1.43 Billion JPY | -0.01% |
| 2023 Q4 | 1.61 Billion JPY | 12.85% |
| 2023 FY | 1.61 Billion JPY | 12.85% |
| 2022 Q3 | 1.62 Billion JPY | 4.31% |
| 2022 FY | 1.43 Billion JPY | -15.89% |
| 2022 Q4 | 1.43 Billion JPY | -11.95% |
| 2022 Q2 | 1.56 Billion JPY | 0.0% |
| 2021 FY | 1.7 Billion JPY | -7.22% |
| 2020 FY | 1.83 Billion JPY | -22.51% |
| 2019 FY | - JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 75.436% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -33.61% |
| GNI Group Ltd. | 62.39 Billion JPY | 97.406% |
| Linical Co., Ltd. | 18.53 Billion JPY | 91.27% |
| Trans Genic Inc. | 9.81 Billion JPY | 83.502% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 71.272% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 76.698% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 72.172% |
| AnGes, Inc. | 28.89 Billion JPY | 94.398% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -86.628% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 98.97% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 68.083% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 62.79% |
| CanBas Co., Ltd. | 2.43 Billion JPY | 33.47% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | 31.802% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 76.645% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | 7.586% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 68.173% |
| PeptiDream Inc. | 67.12 Billion JPY | 97.589% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | 20.681% |
| Ribomic Inc. | 3.54 Billion JPY | 54.371% |
| SanBio Company Limited | 5.04 Billion JPY | 67.932% |
| Healios K.K. | 15.15 Billion JPY | 89.32% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -31.565% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | 46.333% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -9.797% |
| StemRIM | 9.08 Billion JPY | 82.174% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 76.473% |
| FunPep Company Limited | 2.49 Billion JPY | 35.026% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | 38.19% |
| Stella Pharma Corporation | 3.82 Billion JPY | 57.636% |
| TMS Co., Ltd. | 3.55 Billion JPY | 54.467% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 71.992% |
| Cuorips Inc. | 6.18 Billion JPY | 73.829% |
| K Pharma,Inc. | 3.31 Billion JPY | 51.158% |
| Takara Bio Inc. | 123.2 Billion JPY | 98.686% |
| ReproCELL Incorporated | 9.05 Billion JPY | 82.12% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | 40.391% |
| StemCell Institute Inc. | 6.54 Billion JPY | 75.263% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 76.84% |
| CellSeed Inc. | 2.46 Billion JPY | 34.358% |